Forty-four patients diagnosed with treatment-naïve HER2-positive breast cancer (clinical stage IIA-IIIC) were enrolled to receive neoadjuvant TCbIP therapy between November 2021 and November 2023. Here, ERBB2 is linked to breast carcinoma.